BLAInjectionInjectablePriority Review
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
LOARGYS (pegzilarginase-nbln) by Medica Corp is arg1-d is an inherited metabolic disease characterized by deficiency of the arginase 1 enzyme and associated with the persistent elevation of plasma arginine. First approved in 2026.
Drug data last refreshed 14h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOARGYS (pegzilarginase-nbln) is an injectable enzyme replacement therapy for ARG1-D, a rare inherited metabolic disorder caused by arginase 1 deficiency. The drug provides exogenous arginase 1 enzyme activity to reduce elevated plasma arginine by converting it to urea and ornithine, addressing the underlying biochemical defect.
Growth
Early-stage launch phase with low current commercial maturity; expect commercial team expansion and investment in market development infrastructure.
Mechanism of Action
ARG1-D is an inherited metabolic disease characterized by deficiency of the arginase 1 enzyme and associated with the persistent elevation of plasma arginine. LOARGYS provides an exogenous source of the deficient human arginase 1 enzyme activity in patients with ARG1-D and reduces plasma arginine…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LOARGYS offers opportunity to shape the market for a newly approved rare disease therapy with limited competition and high unmet need. Roles will emphasize rare disease expertise, payer navigation, and building physician networks in a highly specialized patient population.
Brand Manager
Worked on LOARGYS at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.